Disposition of haloperidol pyridinium and reduced haloperidol pyridinium in schizophrenic patients: No relationship with clinical variables during short-term treatment

Journal of Clinical Psychopharmacology

Volumn 20, Issue 2, 2000, Pages 210-219

  Ulrich, Sven ^a   Neuhof, Sabine ^b   Braun, Verena ^b   Danos, Peter ^a   Pester, Uwe ^a   Hoy, Ludwig ^a  

^a UNIVERSITY HOSPITAL MAGDEBURG   (Germany)

^b Psychiatric Clinic   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

HALOPERIDOL; REDUCED HALOPERIDOL;

ADULT; ARTICLE; DRUG BLOOD LEVEL; DRUG METABOLISM; DRUG MONITORING; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RATING SCALE; SCHIZOPHRENIA; TARDIVE DYSKINESIA;

ADULT; ANTIPSYCHOTIC AGENTS; BIOTRANSFORMATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HALOPERIDOL; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PSYCHIATRIC STATUS RATING SCALES; PYRIDINIUM COMPOUNDS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 0034040298     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004714-200004000-00014     Document Type: Article

References (25)

1. Eyles DW, McLennan HR, Jones A, McGrath JJ, Stedman TJ, Pond SM. Quantitative analysis of two pyridinium metabolites of haloperidol in patients with schizophrenia. Clin Pharmacol Ther 1994;56:512-20.
2. Eyles DW, Avent KM, Stedman TJ, Pond SM. Two pyridinium metabolites of haloperidol are present in the brain of patients at post-mortem. Life Sci 1997;60:529-34.
3. Fang J, Baker GB, Silverstone PH, Coutts RT. Involvement of CYP3A4 and CYP2D6 in the metabolism of haloperidol. Cell Mol Neurobiol 1997;17:227-33.
4. Avent KM, Riker RR, Fraser GL, Van der Schyf CJ, Usuki E, Pond SM. Metabolism of haloperidol to pyridinium species in patients receiving high doses intravenously: is HPTP an intermediate? Life Sci 1997;61:2383-90.
5. Eyles DW, McGrath JJ, Pond SM. Formation of pyridinium species of haloperidol in human liver and brain. Psychopharmacology (Berl) 1996;125:214-9.
6. Subramanyam B, Rollema H, Woolf TH, Castagnoli N Jr. Identification of a potentially neurotoxic pyridinium metabolite of haloperidol in rats. Biochem Biophys Res Commun 1990;166: 238-44.
7. +-like neurotoxicity of a pyridinium metabolite derived from haloperidol: in vivo microdialysis and in vitro mitochondrial studies. J Pharmacol Exp Ther 1994;268: 380-7.
8. Bloomquist J, King E, Wright A, Mytilineou C, Kimura K, Castagnoli K, Castagnoli N Jr. 1-Methyl-4-phenylpyridinium-like neurotoxicity of a pyridinium metabolite derived from haloperidol: cell culture and neurotransmitter uptake studies. J Pharmacol Exp Ther 1994;270:822-30.
9. +) on viability and catecholamine levels of cultured PC12 cells. Can J Physiol Pharmacol 1997;75:996-1000.
10. +) towards cultured dopaminergic neuroblastoma cells. Psychopharmacology (Berl) 1995;121: 373-8.
11. Ablordeppey SY, Borne RF. Detection of a neurotoxic quaternary pyridinium metabolite in the liver of haloperidol-treated rats. Pharmacol Biochem Behav 1993;46:739-44.
12. Fang J. Hyperactive behavioural effects induced by intranigral infusion of a pyridinium metabolite of haloperidol in rats. Can J Physiol Pharmacol 1996;74:1359-61.
13. Wright AM, Bempong J, Kirby ML, Barlow RL, Bloomquist JR. Effects of haloperidol metabolites on neurotransmitter uptake and release: possible role in neurotoxicity and tardive dyskinesia. Brain Res 1998;788:215-22.
14. Darby JK, Pasta DJ, Dabiri L, Clark L, Mosbacher D. Haloperidol dose and plasma level variability: toxicity and interindividual and intraindividual variability in the nonresponder patient in the clinical practice setting. J Clin Psychopharmacol 1995;15: 334-40.
15. Ulrich S, Neuhof S, Braun V, Meyer FP. Therapeutic window of serum haloperidol concentration in acute schizophrenia and schizoaffective disorder. Pharmacopsychiatry 1998;31:163-9.
16. Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. Psychol Rep 1962;10:799-812.
17. Overall JE, Gorham DR. Brief Psychiatric Rating Scale. In: Guy W, ed. ECDEU assessment manual for psychopharmacology. Rockville, MD: U.S. Department of Health, Education, and Welfare, 1976:157-69.
18. Palao, DJ, Arauxo A, Brunet M, Bernardo M, Haro JM, Ferrer J, Gonzalez-Monclus E. Haloperidol: therapeutic window in schizophrenia. J Clin Psychopharmacol 1994;14:303-10.
19. Volavka J, Cooper T, Czobor P, Bitter I, Meisner M, Laska E, Gastanaga P, Krakowski M, Chou JCY, Crowner M, Douyon R. Haloperidol blood levels and therapeutic effect. Arch Gen Psychiatry 1992;49:354-61.
20. Simpson AM, Angus JSW. Rating scale for extrapyramidal side effects Acta Psychiatr Scand 1970;212[suppl]:11-9.
21. Ulrich S, Meyer FP, Knorr W, Neuhof S. Megabore capillary gas-liquid chromatographic method with nitrogen-phosphorus selective detection for the assay of haloperidol and reduced halopendol in serum: results of therapeutic drug-monitoring during acute theraphy of 8 schizophrenics. J Chromatogr B Biomed Appl 1995;663:289-96.
22. Gorrod JW, Fang J. On the metabolism of halopendol. Xenobiotica 1993;23:495-508.
23. Stevens A, Mahal A, Gaertner HJ. Haloperidol and reduced haloperidol serum levels: correlation with psychopathology in acute schizophrenia. Pharmacopsychiatry 1992;25:218-23.
24. Spina E, Pisani F, Perucca E. Clinically significant pharmacokinetic drug interactions with carbamazepine: an update. Clin Pharmacokinet 1996;31:198-214.
25. Ulrich S, Wurthmann C, Brosz M, Meyer FP. The relationship between serum concentration and therapeutic effect of haloperidol in patients with acute schizophrenia: a review. Clin Pharmacokinet 1998;34:227-63.